Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy

References

• Kyle RA, Therneau TM, Rajkumar SV et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med.354(13), 1362–1369 (2006).
   PubMed Web of Science ®Google Scholar
• Kelly JJ Jr, Kyle RA, O’Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology31(11), 1480–1483 (1981).
   PubMed Web of Science ®Google Scholar
• Latov N. Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann. Neurol.37(Suppl. 1), S32–S42 (1995).
   PubMedGoogle Scholar
• Gorson KC, Ropper AH, Weinberg DH, Weinstein R. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve24(6), 778–786 (2001).
   PubMed Web of Science ®Google Scholar
• Freddo L, Ariga T, Saito M et al. The neuropathy of plasma cell dyscrasia: binding of IgM M-proteins to peripheral nerve glycolipids. Neurology35(10), 1420–1424 (1985).
   PubMed Web of Science ®Google Scholar
• Vital A, Vital C, Julien J, Baquey A, Steck AJ. Polyneuropathy associated with IgM monoclonal gammopathy. Immunological and pathological study in 31 patients. Acta Neuropathol.79(2), 160–167 (1989).
   PubMed Web of Science ®Google Scholar
• Van den Berg L, Hays AP, Nobile-Orazio E et al. Anti-MAG and anti-SGPG antibodies in neuropathy. Muscle Nerve19(5), 637–643 (1996).
   PubMed Web of Science ®Google Scholar
• Weiss MD, Dalakas MC, Lauter CJ, Willison HJ, Quarles RH. Variability in the binding of anti-MAG and anti-SGPG antibodies to target antigens in demyelinating neuropathy and IgM paraproteinemia. J. Neuroimmunol.95(1–2), 174–184 (1999).
   PubMed Web of Science ®Google Scholar
• Hays AP, Latov N, Takatsu M, Sherman WH. Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein. Neurology37(2), 242–256 (1987).
   PubMed Web of Science ®Google Scholar
• Ilyas AA, Quarles RH, Dalakas MC, Brady RO. Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins. Proc. Natl Acad. Sci. USA82(19), 6697–6700 (1985).
   PubMed Web of Science ®Google Scholar
• Eurelings M, Moons KG, Notermans NC et al. Neuropathy and IgM M-proteins: prognostic value of antibodies to MAG, SGPG, and sulfatide. Neurology56(2), 228–233 (2001).
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain123(Pt 4), 710–717 (2000).
   PubMed Web of Science ®Google Scholar
• Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann. Neurol.30(1), 54–61 (1991).
   PubMed Web of Science ®Google Scholar
• Trojaborg W, Hays AP, van den Berg L, Younger DS, Latov N. Motor conduction parameters in neuropathies associated with anti-MAG antibodies and other types of demyelinating and axonal neuropathies. Muscle Nerve18(7), 730–735 (1995).
   PubMed Web of Science ®Google Scholar
• Magy L, Chassande B, Maisonobe T et al. Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. Eur. J. Neurol.10(6), 677–685 (2003).
   PubMed Web of Science ®Google Scholar
• Simmons Z, Bromberg MB, Feldman EL, Blaivas M. Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle Nerve16(1), 77–83 (1993).
   PubMed Web of Science ®Google Scholar
• Simovic D, Gorson KC, Ropper AH. Comparison of IgM-MGUS and IgG-MGUS polyneuropathy. Acta Neurol. Scand.97(3), 194–200 (1998).
   PubMed Web of Science ®Google Scholar
• Kornberg AJ, Pestronk A. Antibody-associated polyneuropathy syndromes: principles and treatment. Semin. Neurol.23(2), 181–190 (2003).
   PubMed Web of Science ®Google Scholar
• Notermans NC, Lokhorst HM, Franssen H et al. Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance. Neurology47(5), 1227–1233 (1996).
   PubMed Web of Science ®Google Scholar
• Mariette X, Chastang C, Clavelou P et al. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J. Neurol. Neurosurg. Psychiatr.63(1), 28–34 (1997).
   PubMed Web of Science ®Google Scholar
• Cook D, Dalakas M, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology40(2), 212–214 (1990).
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Chevret S, Leger JM et al. Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. IgM-associated Polyneuropathy Study Group. J. Neurol. Neurosurg. Psychiatr.59(3), 243–247 (1995).
   PubMed Web of Science ®Google Scholar
• Latov N, Sherman WH. Therapy of neuropathy associated with anti-MAG IgM monoclonal gammopathy with rituxan. Neurology52(Suppl. 2), A551 (1999).
   PubMed Web of Science ®Google Scholar
• Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology52(8), 1701–1704 (1999).
   PubMed Web of Science ®Google Scholar
• Pestronk A, Florence J, Miller T et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J. Neurol. Neurosurg. Psychiatr.74(4), 485–489 (2003).
   PubMed Web of Science ®Google Scholar
• Renaud S, Gregor M, Fuhr P et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve27(5), 611–615 (2003).
   PubMed Web of Science ®Google Scholar
• Siddiqui K, Cahalane E, Keogan M, Hardiman O. Chronic ataxic neuropathy with cold agglutinins: atypical phenotype and response to anti-CD20 antibodies. Neurology61(9), 1307–1308 (2003).
   PubMed Web of Science ®Google Scholar
• Briani C, Zara G, Zambello R et al. Rituximab-responsive CIDP. Eur. J. Neurol.11(11), 788 (2004).
   PubMed Web of Science ®Google Scholar
• Goldfarb AR, Weimer LH, Brannagan TH 3rd. Rituximab treatment of an IgM monoclonal autonomic and sensory neuropathy. Muscle Nerve31(4), 510–515 (2005).
   PubMed Web of Science ®Google Scholar
• Cai FZ, Ahern M, Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J. Rheumatol.33(6), 1197–1198 (2006).
   PubMed Web of Science ®Google Scholar
• Kilidireas C, Anagnostopoulos A, Karandreas N, Mouselimi L, Dimopoulos MA. Rituximab therapy in monoclonal IgM-related neuropathies. Leuk. Lymphoma47(5), 859–864 (2006).
   PubMed Web of Science ®Google Scholar
• Renaud S, Fuhr P, Gregor M et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology66(5), 742–744 (2006).
   PubMed Web of Science ®Google Scholar
• Gorson KC. Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). J. Clin. Apher.14(3), 149–153 (1999).
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Low PA, Windebank AJ et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N. Engl. J. Med.325(21), 1482–1486 (1991).
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev.31(6), 456–473 (2005).
   PubMed Web of Science ®Google Scholar
• Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs63(8), 803–843 (2003).
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood83(2), 435–445 (1994).
   PubMed Web of Science ®Google Scholar
• Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu. Rev. Med.55, 477–503 (2004).
   PubMed Web of Science ®Google Scholar
• O’Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics48(2), 125–132 (1998).
   PubMed Web of Science ®Google Scholar
• Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology107(2), 176–182 (2002).
   PubMed Web of Science ®Google Scholar
• Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J. Clin. Oncol.17(6), 1851–1857 (1999).
   PubMed Web of Science ®Google Scholar
• Rouziere AS, Kneitz C, Palanichamy A, Dorner T, Tony HP. Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res. Ther.7(4), R714–R724 (2005).
   Google Scholar
• Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transplant6(5), 859–866 (2006).
   PubMed Web of Science ®Google Scholar
• Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol.174(2), 817–826 (2005).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol.16(8), 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann. Oncol.9(9), 995–1001 (1998).
   PubMed Web of Science ®Google Scholar
• Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J. Clin. Pharmacol.45(7), 792–801 (2005).
   PubMed Web of Science ®Google Scholar
• Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin’s lymphoma? Ann. Oncol.11(3), 374–375 (2000).
   PubMed Web of Science ®Google Scholar
• Rojas-Garcia R, Gallardo E, de Andres I et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology61(12), 1814–1816 (2003).
   PubMed Web of Science ®Google Scholar
• Broglio L, Lauria G. Worsening after rituximab treatment in anti-MAG neuropathy. Muscle Nerve32(3), 378–379 (2005).
   PubMed Web of Science ®Google Scholar
• Treon SP, Hansen M, Branagan AR et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom’s macroglobulinemia. J. Clin. Oncol.23(3), 474–481 (2005).
   PubMed Web of Science ®Google Scholar
• Stuve O, Cepok S, Elias B et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch. Neurol.62(10), 1620–1623 (2005).
   PubMed Web of Science ®Google Scholar
• Baig S, Jiang YP, Olsson T, Cruz M, Link H. Cells secreting anti-MAG antibody occur in cerebrospinal fluid and bone marrow in patients with polyneuropathy associated with M component. Brain114(Pt 1B), 573–583 (1991).
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med.350(25), 2572–2581 (2004).
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol.19(8), 2165–2170 (2001).
   PubMed Web of Science ®Google Scholar
• Treon SP, Emmanouilides C, Kimby E et al. Extended rituximab therapy in Waldenstrom’s macroglobulinemia. Ann. Oncol.16(1), 132–138 (2005).
   PubMed Web of Science ®Google Scholar
• Lambotte O, Kotb R, Maigne G et al. Efficacy of rituximab in refractory polymyositis. J. Rheumatol.32(7), 1369–1370 (2005).
   PubMed Web of Science ®Google Scholar
• Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum.52(2), 601–607 (2005).
   PubMed Web of Science ®Google Scholar
• Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology55(7), 1062–1063 (2000).
   PubMed Web of Science ®Google Scholar
• Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve33(4), 575–580 (2005).
   Web of Science ®Google Scholar
• Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology63(11), 2178–2179 (2004).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Czerwinski DK et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood84(8), 2457–2466 (1994).
   PubMed Web of Science ®Google Scholar
• Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J. Rheumatol.32(11), 2109–2115 (2005).
   PubMed Web of Science ®Google Scholar
• Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom’s macroglobulinemia. J. Clin. Oncol.24(1), E3 (2006).
   PubMedGoogle Scholar
• Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 “what do B-cells do?” Clin. Immunol.117(3), 207–213 (2005).
   PubMed Web of Science ®Google Scholar
• Suzan F, Ammour M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N. Engl. J. Med.345(13), 1000 (2001).
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Kanamori H, Mori A et al. Reactivation of hepatitis B virus with rituximab. Expert Opin. Drug Saf.4(3), 599–608 (2005).
   PubMedGoogle Scholar
• Foxton MR, Knight L, Knisely AS et al. Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab. Liver Transpl.11(7), 839–842 (2005).
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Soardo G, Romano G et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford)45(7), 842–846 (2006).
   PubMed Web of Science ®Google Scholar
• Sansonno D, De Re V, Lauletta G et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood101(10), 3818–3826 (2003).
   PubMed Web of Science ®Google Scholar
• Klepfish A, Schattner A, Shvidel L et al. Successful treatment of aggressive HIV-associated non-Hodgkin’s lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option. Leuk. Lymphoma44(2), 349–351 (2003).
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford)44(12), 1542–1545 (2005).
   PubMed Web of Science ®Google Scholar
• Leonard JP. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Hematology Am. Soc. Hematol. Educ. Program335–339 (2005).
   PubMedGoogle Scholar
• Vugmeyster Y, Beyer J, Howell K et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J. Immunother.28(3), 212–219 (2005).
   PubMed Web of Science ®Google Scholar
• Barohn RJ, Rashid I, McVey AL et al. Rituximab for the treatment of IgM associated polyneuropathies. J. Peripher. Nerv. Syst.10(Suppl. 1), 4 (2005).
   Google Scholar
• Weide R, Heymanns J, Koppler H. The polyneuropathy associated with Waldenstrom’s macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. Br. J. Haematol.109(4), 838–841 (2000).
   PubMed Web of Science ®Google Scholar
• Delarue R, Deau B, Alyanakian M-A, Varet BR, Hermin O. Rituximab in anti-MAG associated neuropathy: a monocentric experience. Blood104(11), A4909 (2004).
   Google Scholar